Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (12): 1181-1189.DOI: 10.3969/j.issn.1673-8640.2024.12.009
Previous Articles Next Articles
ZOU Chen1, XU Runhao2, DING Yi3, ZHANG Jie2, WENG Wenhao1, WANG Zhenhua4, CAO Yun2(
)
Received:2024-05-06
Revised:2024-08-27
Online:2024-12-30
Published:2025-01-06
CLC Number:
ZOU Chen, XU Runhao, DING Yi, ZHANG Jie, WENG Wenhao, WANG Zhenhua, CAO Yun. Colorectal cancer screening model based on ProteomeXchange database[J]. Laboratory Medicine, 2024, 39(12): 1181-1189.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.12.009
| 蛋白ID | 蛋白基因符号 | 蛋白名称 | 生物学进程① | 细胞成分② | 分子功能③ | KEGG通路④ | 连接节点⑤ | 差异倍数 | 候选蛋白 |
|---|---|---|---|---|---|---|---|---|---|
| P02647 | APOA1 | APOA1 | 0 | 8 | 0 | 2 | 20 | 0.72 | apo A1 |
| P02656 | APOC3 | APOC3 | 0 | 3 | 0 | 2 | 29 | 1.37 | apo C3 |
| P00450 | CP | CER | 0 | 2 | 0 | 0 | 23 | 1.45 | CER |
| P02741 | CRP | CRP | 2 | 0 | 1 | 0 | 16 | 2.59 | CRP |
| P0C0L4 | C4A | C4A | 5 | 2 | 0 | 5 | 19 | 1.90 | C4 |
| P02671 | FGA | FGA | 7 | 10 | 2 | 3 | 38 | 2.19 | Fib |
| P02751 | FN1 | FN | 0 | 10 | 3 | 0 | 29 | 0.02 | FN |
| P00390 | GSR | GR | 1 | 3 | 0 | 0 | 22 | 0.30 | GR |
| P02787 | TF | TRF | 1 | 5 | 0 | 0 | 17 | 0.57 | TRF |
| P61769 | B2M | β2-MG | 1 | 4 | 1 | 0 | 24 | 1.59 | β2-MG |
| 蛋白ID | 蛋白基因符号 | 蛋白名称 | 生物学进程① | 细胞成分② | 分子功能③ | KEGG通路④ | 连接节点⑤ | 差异倍数 | 候选蛋白 |
|---|---|---|---|---|---|---|---|---|---|
| P02647 | APOA1 | APOA1 | 0 | 8 | 0 | 2 | 20 | 0.72 | apo A1 |
| P02656 | APOC3 | APOC3 | 0 | 3 | 0 | 2 | 29 | 1.37 | apo C3 |
| P00450 | CP | CER | 0 | 2 | 0 | 0 | 23 | 1.45 | CER |
| P02741 | CRP | CRP | 2 | 0 | 1 | 0 | 16 | 2.59 | CRP |
| P0C0L4 | C4A | C4A | 5 | 2 | 0 | 5 | 19 | 1.90 | C4 |
| P02671 | FGA | FGA | 7 | 10 | 2 | 3 | 38 | 2.19 | Fib |
| P02751 | FN1 | FN | 0 | 10 | 3 | 0 | 29 | 0.02 | FN |
| P00390 | GSR | GR | 1 | 3 | 0 | 0 | 22 | 0.30 | GR |
| P02787 | TF | TRF | 1 | 5 | 0 | 0 | 17 | 0.57 | TRF |
| P61769 | B2M | β2-MG | 1 | 4 | 1 | 0 | 24 | 1.59 | β2-MG |
| 组别 | 例数 | apo A1/(g·L-1) | apo C3/(mg·L-1) | CER/(g·L-1) | CRP/(mg·L-1) | C4/(g·L-1) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRC组 | 108 | 1.15±0.26 | 79.5(68.9~96.4) | 0.27(0.24~0.32) | 10.75(2.86~48.05) | 0.26(0.21~0.32) | ||||||
| 正常对照组 | 100 | 1.61±0.27 | 104.1(87.7~129.3) | 0.24(0.22~0.27) | 2.86(2.86~2.86) | 0.22(0.18~0.27) | ||||||
| 统计值 | 12.488 | -6.531 | -4.509 | -8.586 | -4.059 | |||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
| 组别 | FN/(mg·L-1) | Fib/(g·L-1) | GR/(U·L-1) | TRF/(g·L-1) | β2-MG/(mg·L-1) | |||||||
| CRC组 | 284.05(215.50~331.10) | 3.21(2.57~4.06) | 46.26±10.17 | 2.12±0.53 | 2.05(1.67~2.58) | |||||||
| 正常对照组 | 349.50(304.93~409.48) | 2.74(2.36~3.22) | 52.99±7.51 | 2.56±0.37 | 1.57(1.34~1.81) | |||||||
| 统计值 | -5.828 | -4.042 | 5.386 | 6.808 | -6.940 | |||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
| 组别 | CEA/(ng·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | CA50/(U·mL-1) | CA72-4/(U·mL-1) | |||||||
| CRC组 | 3.46(1.81~8.48) | 11.20(5.95~17.80) | 5.17(2.89~11.89) | 6.48(3.94~11.22) | 1.75(1.50~3.87) | |||||||
| 正常对照组 | 1.58(1.01~2.25) | 8.14(5.80~11.68) | 5.18(3.52~7.34) | 5.46(3.15~9.03) | 1.63(1.50~2.99) | |||||||
| 统计值 | -6.716 | -2.848 | -0.730 | -1.788 | -1.207 | |||||||
| P值 | <0.001 | 0.004 | 0.466 | 0.074 | 0.228 | |||||||
| 组别 | 例数 | apo A1/(g·L-1) | apo C3/(mg·L-1) | CER/(g·L-1) | CRP/(mg·L-1) | C4/(g·L-1) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRC组 | 108 | 1.15±0.26 | 79.5(68.9~96.4) | 0.27(0.24~0.32) | 10.75(2.86~48.05) | 0.26(0.21~0.32) | ||||||
| 正常对照组 | 100 | 1.61±0.27 | 104.1(87.7~129.3) | 0.24(0.22~0.27) | 2.86(2.86~2.86) | 0.22(0.18~0.27) | ||||||
| 统计值 | 12.488 | -6.531 | -4.509 | -8.586 | -4.059 | |||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
| 组别 | FN/(mg·L-1) | Fib/(g·L-1) | GR/(U·L-1) | TRF/(g·L-1) | β2-MG/(mg·L-1) | |||||||
| CRC组 | 284.05(215.50~331.10) | 3.21(2.57~4.06) | 46.26±10.17 | 2.12±0.53 | 2.05(1.67~2.58) | |||||||
| 正常对照组 | 349.50(304.93~409.48) | 2.74(2.36~3.22) | 52.99±7.51 | 2.56±0.37 | 1.57(1.34~1.81) | |||||||
| 统计值 | -5.828 | -4.042 | 5.386 | 6.808 | -6.940 | |||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
| 组别 | CEA/(ng·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | CA50/(U·mL-1) | CA72-4/(U·mL-1) | |||||||
| CRC组 | 3.46(1.81~8.48) | 11.20(5.95~17.80) | 5.17(2.89~11.89) | 6.48(3.94~11.22) | 1.75(1.50~3.87) | |||||||
| 正常对照组 | 1.58(1.01~2.25) | 8.14(5.80~11.68) | 5.18(3.52~7.34) | 5.46(3.15~9.03) | 1.63(1.50~2.99) | |||||||
| 统计值 | -6.716 | -2.848 | -0.730 | -1.788 | -1.207 | |||||||
| P值 | <0.001 | 0.004 | 0.466 | 0.074 | 0.228 | |||||||
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| apo A1 | 0.898(0.849~0.936) | 1.32 g·L-1 | 81.48 | 86.00 | 0.67 |
| apo C3 | 0.762(0.698~0.818) | 82.9 mg·L-1 | 56.48 | 85.00 | 0.41 |
| CER | 0.681(0.613~0.743) | 0.25 g·L-1 | 63.89 | 66.00 | 0.30 |
| CRP | 0.803(0.742~0.854) | 3.26 mg·L-1 | 65.74 | 92.00 | 0.58 |
| C4 | 0.663(0.594~0.727) | 0.23 g·L-1 | 66.67 | 58.00 | 0.25 |
| Fib | 0.662(0.589~0.736) | 3.54 g·L-1 | 37.96 | 92.00 | 0.30 |
| FN | 0.734(0.669~0.793) | 290.10 mg·L-1 | 55.56 | 83.00 | 0.39 |
| GR | 0.749(0.684~0.806) | 45.80 U·L-1 | 57.41 | 85.00 | 0.42 |
| TRF | 0.752(0.687~0.809) | 2.12 g·L-1 | 54.63 | 92.00 | 0.47 |
| β2-MG | 0.779(0.716~0.833) | 2.00 mg·L-1 | 55.56 | 90.00 | 0.46 |
| CEA | 0.770(0.707~0.825) | 2.52 ng·mL-1 | 62.96 | 82.00 | 0.45 |
| CA19-9 | 0.614(0.545~0.681) | 11.90 U·mL-1 | 48.15 | 77.00 | 0.25 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| apo A1 | 0.898(0.849~0.936) | 1.32 g·L-1 | 81.48 | 86.00 | 0.67 |
| apo C3 | 0.762(0.698~0.818) | 82.9 mg·L-1 | 56.48 | 85.00 | 0.41 |
| CER | 0.681(0.613~0.743) | 0.25 g·L-1 | 63.89 | 66.00 | 0.30 |
| CRP | 0.803(0.742~0.854) | 3.26 mg·L-1 | 65.74 | 92.00 | 0.58 |
| C4 | 0.663(0.594~0.727) | 0.23 g·L-1 | 66.67 | 58.00 | 0.25 |
| Fib | 0.662(0.589~0.736) | 3.54 g·L-1 | 37.96 | 92.00 | 0.30 |
| FN | 0.734(0.669~0.793) | 290.10 mg·L-1 | 55.56 | 83.00 | 0.39 |
| GR | 0.749(0.684~0.806) | 45.80 U·L-1 | 57.41 | 85.00 | 0.42 |
| TRF | 0.752(0.687~0.809) | 2.12 g·L-1 | 54.63 | 92.00 | 0.47 |
| β2-MG | 0.779(0.716~0.833) | 2.00 mg·L-1 | 55.56 | 90.00 | 0.46 |
| CEA | 0.770(0.707~0.825) | 2.52 ng·mL-1 | 62.96 | 82.00 | 0.45 |
| CA19-9 | 0.614(0.545~0.681) | 11.90 U·mL-1 | 48.15 | 77.00 | 0.25 |
| 模型(步数) | 纳入模型的生物标志物 | 移除项① | AUC | 敏感性/% | 特异性/% | P值② |
|---|---|---|---|---|---|---|
| 1 | apo A1、CRP、FN、GR、TRF、β2-MG、CEA | 0.963 | 87.21 | 93.75 | ||
| 2 | apo A1、CRP、FN、GR、TRF、CEA | β2-MG | 0.963 | 87.21 | 93.75 | 0.935 |
| 3③ | apo A1、CRP、FN、TRF、CEA | GR | 0.959 | 87.21 | 92.50 | 0.145 |
| 4 | apo A1、CRP、FN、CEA | TRF | 0.955 | 86.05 | 90.00 | 0.048 |
| 模型(步数) | 纳入模型的生物标志物 | 移除项① | AUC | 敏感性/% | 特异性/% | P值② |
|---|---|---|---|---|---|---|
| 1 | apo A1、CRP、FN、GR、TRF、β2-MG、CEA | 0.963 | 87.21 | 93.75 | ||
| 2 | apo A1、CRP、FN、GR、TRF、CEA | β2-MG | 0.963 | 87.21 | 93.75 | 0.935 |
| 3③ | apo A1、CRP、FN、TRF、CEA | GR | 0.959 | 87.21 | 92.50 | 0.145 |
| 4 | apo A1、CRP、FN、CEA | TRF | 0.955 | 86.05 | 90.00 | 0.048 |
| [1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
| [2] | WOLF A M D, FONTHAM E T H, CHURCH T R, et al. Colorectal cancer screening for average-risk adults:2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2018, 68(4):250-281. |
| [3] |
BRENNER H, KLOOR M, POX C P. Colorectal cancer[J]. Lancet, 2014, 383(9927):1490-1502.
DOI PMID |
| [4] | FANG Z, HE M, SONG M. Serum lipid profiles and risk of colorectal cancer:a prospective cohort study in the UK Biobank[J]. Br J Cancer, 2021, 124(3):663-670. |
| [5] | LEE P Y, CHIN S F, LOW T Y, et al. Probing the colorectal cancer proteome for biomarkers:current status and perspectives[J]. J Proteomics, 2018,187:93-105. |
| [6] | HELSINGEN L M, VANDVIK P O, JODAL H C, et al. Colorectal cancer screening with faecal immunochemical testing,sigmoidoscopy or colonoscopy:a clinical practice guideline[J]. BMJ, 2019,367:l5515. |
| [7] | REUMKENS A, RONDAGH E J, BAKKER C M, et al. Post-colonoscopy complications:a systematic review,time trends,and meta-analysis of population-based studies[J]. Am J Gastroenterol, 2016, 111(8):1092-1101. |
| [8] | SHAUKAT A, KAHI C J, BURKE C A, et al. ACG clinical guidelines:colorectal cancer screening 2021[J]. Am J Gastroenterol, 2021, 116(3):458-479. |
| [9] | 房静远, 李延青, 陈萦晅, 等. 中国结直肠肿瘤综合预防共识意见(2021年,上海)[J]. 胃肠病学, 2021, 26(5):279-311. |
| [10] | BENAMOUZIG R, BARRÉ S, SAURIN J C, et al. Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals[J]. Therap Adv Gastroenterol, 2021,14:17562848211002359. |
| [11] | IMPERIALE T F, RANSOHOFF D F, ITZKOWITZ S H, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14):1287-1297. |
| [12] |
上海市抗癌协会大肠癌专业委员会. 结直肠癌早筛、早诊、早治上海方案(2023年版)[J]. 中国癌症杂志, 2024, 34(1):13-66.
DOI |
| [13] | URBIOLA-SALVADOR V, JABOSKA A, MIROSZEWSKA D, et al. Plasma protein changes reflect colorectal cancer development and associated inflammation[J]. Front Oncol, 2023,13:1158261. |
| [14] | NICOLINI A, FERRARI P, DUFFY M J, et al. Intensive risk-adjusted follow-up with the CEA,TPA,CA19.9,and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences:effect on survival[J]. Arch Surg, 2010, 145(12):1177-1183. |
| [15] | BHARDWAJ M, GIES A, WERNER S, et al. Blood-based protein signatures for early detection of colorectal cancer:a systematic review[J]. Clin Transl Gastroenterol, 2017, 8(11):e128. |
| [16] | HORNBROOK M C, GOSHEN R, CHOMAN E, et al. Early colorectal cancer detected by machine learning model using gender,age,and complete blood count data[J]. Dig Dis Sci, 2017, 62(10):2719-2727. |
| [17] | ZHANG Z. An in vitro diagnostic multivariate index assay(IVDMIA)for ovarian cancer:harvesting the power of multiple biomarkers[J]. Rev Obstet Gynecol, 2012, 5(1):35-41. |
| [18] | ZHOU H, WANG X C, YUAN B B, et al. Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer[J]. J Physiol Pharmacol, 2022, 73(3):443-449. |
| [19] | PANKAJ J, KUMARI J R, KIM W, et al. Insulin-like growth factor-1,IGF-binding protein-3,C-peptide and colorectal cancer:a case-control study[J]. Asian Pac J Cancer Prev, 2015, 16(9):3735-3740. |
| [20] | VORONOVA V, GLYBOCHKO P, SVISTUNOV A, et al. Diagnostic value of combinatorial markers in colorectal carcinoma[J]. Front Oncol, 2020,10:832. |
| [21] |
KWON Y, PARK S J, NGUYEN B T, et al. Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling[J]. Sci Rep, 2021, 11(1):17130.
DOI PMID |
| [22] | MARTÍN-GARCÍA D, GARCÍA-ARANDA M, REDONDO M. Biomarker identification through proteomics in colorectal cancer[J]. Int J Mol Sci, 2024, 25(4):2283. |
| [23] |
SHI Y, LIU Z. Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer[J]. J Cell Mol Med, 2020, 24(15):8363-8367.
DOI PMID |
| [24] | SANTOS M D, BARROS I, BRANDÃO P, et al. Amino acid profiles in the biological fluids and tumor tissue of CRC patients[J]. Cancers(Basel), 2023, 16(1):69. |
| [25] |
兰俊, 路舒婷, 杨健睿. 结直肠癌患者血清IL-26、IL-27水平检测的临床意义[J]. 检验医学, 2024, 39(1):7-12.
DOI |
| [1] | GAO Xiantong, YAO Qianqian, RU Lijuan. Establishment and clinical application evaluation of early warning model for acute pancreatitis complicated with AKI [J]. Laboratory Medicine, 2025, 40(8): 775-781. |
| [2] | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine Clinical Laboratory Society of Chinese Association of Integrative Medicine, Tumor Immunology Branch of Shanghai Society for Immunology Molecular Diagnostics Society of Shanghai Medical Association. Expert consensus on non-invasive laboratory diagnosis for hepatic fibrosis [J]. Laboratory Medicine, 2025, 40(7): 625-641. |
| [3] | HUANG Ren, SHI Weizhong, LU Renquan, GUO Lin, WANG Yanchun. Combined determination of Septin9 gene methylation and SDC2 gene methylation in auxiliary diagnosis of colorectal cancer [J]. Laboratory Medicine, 2025, 40(6): 519-524. |
| [4] | WU Yazhou, LI Hanhua, MENG Leijun, CHEN Xuefei, SUN Yuhan, WENG Wenhao, ZHENG Bing. Fusobacterium nucleatum promoting chemoresistance of colorectal cancer cells via lncRNA XIST [J]. Laboratory Medicine, 2025, 40(5): 428-436. |
| [5] | YU Jiajie, ZHANG Zhizhi, LUO Qingqiong, KE Xing. Predicting early colorectal tumor risk using a deep learning model based on multiple serum tumor markers [J]. Laboratory Medicine, 2025, 40(3): 253-258. |
| [6] | DONG Yihan, LIU Shiming, WANG Yong, YUE Dan, WANG Rui. Research progress of exosome extraction and identification in renal cancer [J]. Laboratory Medicine, 2025, 40(11): 1118-1125. |
| [7] | GUO Fengxia, HU Bing, SHA Yanhua. Role of methyltransferase-like protein 14 in patients with coronary heart disease [J]. Laboratory Medicine, 2025, 40(1): 54-58. |
| [8] | ZHENG Hui, CHEN Yingxiu, YE Lüyin, LU Renquan, GUO Lin. Relationship between peripheral blood T lymphocyte subsets and tumor progression in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(4): 330-335. |
| [9] | XU Yunchuan, HUANGFU Yuchan, MA Yanhui. Effect of highly expressed IL-35 on Th1 and Th17 plasticity in colorectal cancer [J]. Laboratory Medicine, 2024, 39(4): 343-350. |
| [10] | LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12. |
| [11] | SUN Chuanyu, ZHAO Xiaojun, GE Shengyang, ZHANG Yang. Transcription factors in prostate cancer progression [J]. Laboratory Medicine, 2023, 38(9): 818-824. |
| [12] | LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832. |
| [13] | SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789. |
| [14] | ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633. |
| [15] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||